Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.
Atomo Diagnostics Ltd has notified the market of a new issue of unquoted equity securities in the form of options. The company, listed on the ASX under code AT1, continues to leverage capital market instruments to support its activities in the medical diagnostics sector.
The company will issue 45,454,536 unquoted options, each exercisable at $0.045 and expiring on 8 October 2028. These options are part of a previously announced transaction and are not intended to be quoted on the ASX, signalling a structured incentive or funding mechanism for selected stakeholders rather than a broad public offering.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd is an Australian-listed medical diagnostics company focused on rapid point-of-care testing technologies. The company develops and supplies integrated blood test devices aimed at improving accessibility and usability for screening and diagnostic applications in healthcare and related markets.
Average Trading Volume: 2,045,256
Technical Sentiment Signal: Sell
Current Market Cap: A$25.93M
See more insights into AT1 stock on TipRanks’ Stock Analysis page.